Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-1 and receptor-2 agonists for cancer therapy

Bibliography

• Humphreys RC, Halpern W. TRAIL receptors: Target for cancer therapy. In: Khosravi-Far R, White E, eds. Programmed cell death in cancer progression and therapy. Berlin: Springer, 2008:127-58
   Google Scholar
• Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor–related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol 2008;26:3621-30
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
   PubMed Web of Science ®Google Scholar
• Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008;7:1001-12
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8:782-98
   PubMed Web of Science ®Google Scholar
• Corallini F, Rimondi E, Secchiero P. TRAIL and osteoprotegerin: a role in endothelial physiopathology? Front Biosci 2008;13:135-47
   PubMed Web of Science ®Google Scholar
• Falschlehner C, Schaefer U, Walczak H. Following TRAIL's path in the immune system. Immunology 2009;127:145-54
   PubMed Web of Science ®Google Scholar
• Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol 2007;35:495-516
   PubMed Web of Science ®Google Scholar
• Meng XW, Lee SH, Dai H, Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. J Biol Chem 2007;282:29831-46
   PubMed Web of Science ®Google Scholar
• Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer 2008;8:782-98
   PubMed Web of Science ®Google Scholar
• Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature 2004;432:307-15
   PubMed Web of Science ®Google Scholar
• Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005;12:228-37
   PubMed Web of Science ®Google Scholar
• Thorburn A, Behbakht K, Ford H. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Update 2008;11:17-24
   PubMed Web of Science ®Google Scholar
• Nawrocki ST, Carew JS, Douglas L, Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res 2007;67:6987-94
   PubMed Web of Science ®Google Scholar
• Saulle E, Petronelli A, Pasquini L, Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis 2007;12:635-55
   PubMed Web of Science ®Google Scholar
• Locklin RM, Federici E, Espina B, Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis. Mol Cancer Ther 2007;6:3219-28
   PubMed Web of Science ®Google Scholar
• Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res 2007;13:4556-64
   PubMed Web of Science ®Google Scholar
• Luster TA, Carrell JA, McCormick K, Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Mol Cancer Ther 2009;8:292-302
   PubMed Web of Science ®Google Scholar
• MacFarlane M, Harper N, Snowden RT, Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 2002;21:6809-18
   PubMed Web of Science ®Google Scholar
• MacFarlane M, Inoue S, Kohlhaas SL, Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 2005;12:773-82
   PubMed Web of Science ®Google Scholar
• Kelley RF, Totpal K, Lindstrom SH, Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005;280:2205-12
   PubMed Web of Science ®Google Scholar
• Elrod HA, Sun SY. Modulation of death receptors by cancer therapeutic agents. Cancer Biol Ther 2008;7:163-73
   PubMed Web of Science ®Google Scholar
• Yu JW, Shi Y. Flip and the death effector domain family. Oncogene 2008;27:6216-27
   PubMed Web of Science ®Google Scholar
• Ozören N, El-Deiry WS. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 2003;13:135-47
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999;11:255-60
   PubMed Web of Science ®Google Scholar
• Clancy L, Mruk K, Archer K, Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 2005;102:18099-104
   PubMed Web of Science ®Google Scholar
• Mérino D, Lalaoui N, Morizot A, Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006;26:7046-55
   PubMed Web of Science ®Google Scholar
• Ren YG, Wagner KW, Knee DA, Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle. Mol Biol Cell 2004;15:5064-74
   PubMed Web of Science ®Google Scholar
• Bantel H, Schulze-Osthoff K. Apoptosis in hepatitis C virus infection. Cell Death Differ 2003;10:S48-58
   PubMed Web of Science ®Google Scholar
• Lin T, Gu J, Zhang L, Targeted expression of green fluorescent protein/tumor necrosis factor-related apoptosis-inducing ligand fusion protein from human telomerase reverse transcriptase promoter elicits antitumor activity without toxic effects on primary human hepatocytes. Cancer Res 2002;62:3620-5
   PubMed Web of Science ®Google Scholar
• Matsuda T, Almasan A, Tomita M, Dengue virus-induced apoptosis in hepatic cells is partly mediated by Apo2 ligand/tumour necrosis factor-related apoptosis-inducing ligand. J Gen Virol 2005;86:1055-65
   PubMed Web of Science ®Google Scholar
• Dunn C, Brunetto M, Reynolds G, Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med 2007;204:667-80
   PubMed Web of Science ®Google Scholar
• Mundt B, Wirth T, Zender L, Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake. Gut 2005;54:1590-1596
   PubMed Web of Science ®Google Scholar
• Zhu H, Dong H, Eksioglu E, Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology 2007;133:1649-59
   PubMed Web of Science ®Google Scholar
• Pukac L, Kanakaraj P, Humphreys R, HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 2005;92:1430-41
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Mita M, Meropol NJ, Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor–related apoptosis-inducing ligand receptor-1. J Clin Oncol 2007;25:1390-5
   PubMed Web of Science ®Google Scholar
• Moretto P, Hotte SJ. Targeting apoptosis: Preclinical and early clinical experience with mapatumumab, an agonist monoclonal antibody targeting TRAIL-R1. Expert Opin Investig Drugs 2009;18:311-25
   PubMed Web of Science ®Google Scholar
• Ménoret E, Gomez-Bougie P, Geffroy-Luseau A, Mcl-1L cleavage is involved in TRAIL-R1– and TRAIL-R2–mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells. Blood 2006;108:1346-52
   PubMed Web of Science ®Google Scholar
• Abdulghani J, Mayes P, Dicker D, Sorafenib sensitizes hepatocellular carcinoma cells to TRAIL or TRAIL receptor agonist antibodies. AACR Meeting Abstracts 2008;49:833
   Google Scholar
• Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res 2007;13:4556-64
   PubMed Web of Science ®Google Scholar
• Smith MR, Jin F, Joshi I. Bortezomib sensitizes non–Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2. Clin Cancer Res 2007;13:5528s-34s
   PubMed Web of Science ®Google Scholar
• Kandasamy K, Kraft AS. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3′-untranslated region. Mol Cancer Ther 2008;7:1091-100
   PubMed Web of Science ®Google Scholar
• Gong J, Yang D, Kohanim S, Novel in vivo imaging shows up-regulation of death receptors by paclitaxel and correlates with enhanced antitumor effects of receptor agonist antibodies. Mol Cancer Ther 2006;5:2991-3000
   PubMed Web of Science ®Google Scholar
• Humphreys R, McCormick K, Taslim L, The TRAIL receptor 1 antibody, mapatumumab, synergizes with cisplatin or doxorubicin to enhance anti-tumor activity in hepatocellular carcinoma. AACR Meeting Abstracts 2008;49:1561
   Google Scholar
• Sun D, McCormick K, Taslim L, Bortezomib sensitizes TRAIL-R mAb resistant NSCLC tumors to apoptosis in combination with TRAIL-R agonistic mAbs: mapatumumab (HGS-ETR1) and lexatumumab (HGS-ETR2). AACR Meeting Abstracts 2007;48:5177
   Google Scholar
• Frew AJ, Lindemann RK, Martin BP, Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci USA 2008;105:11317-22
   PubMed Web of Science ®Google Scholar
• Inoue S, Mai A, Dyer MJS, Cohen GM. Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-Induced apoptosis. Cancer Res 2006;66:6785-92
   PubMed Web of Science ®Google Scholar
• Mendoza FJ, Ishdorj G, Hu X, Gibson SB. Death receptor-4 (DR4) expression is regulated by transcription factor NF-κB in response to etoposide treatment. Apoptosis 2008;13:756-70
   PubMed Web of Science ®Google Scholar
• Belyanskaya LL, Marti TM, Hopkins-Donaldson S, Human agonistic TRAIL receptor antibodies mapatumumab and lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin. Mol Cancer 2007;6:66-78
   PubMedGoogle Scholar
• Jin X, Wu XX, Abdel-Muneem Nouh MA, Kakehi Y. Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin. J Urol 2007;177:1894-9
   PubMed Web of Science ®Google Scholar
• Marini P, Denzinger S, Schiller D, Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: Enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 2006;25:5145-54
   PubMed Web of Science ®Google Scholar
• Georgakis GV, Li Y, Humphreys R, Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: Induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005;130:501-10
   PubMed Web of Science ®Google Scholar
• Nawrocki S, Douglas L, Tillman DM, Ligation of TRAIL receptors synergistically enhances therapeutic response to 5-fluorouracil (FUra), leucovorin (LV) and interferon-gamma (IFN-gamma) in human colon carcinoma cell lines (cc) both in vitro and in xenograft models. AACR Meeting Abstracts 2006;47:127
   Google Scholar
• Georgakis GV, Li Y, Rassidakis GZ, Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 2006;12:584-90
   PubMed Web of Science ®Google Scholar
• Hotte SJ, Hirte HW, Chen EX, A Phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin Cancer Res 2008;14:3450-5
   PubMed Web of Science ®Google Scholar
• Greco FA, Bonomi P, Crawford J, Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 2008;61:82-90
   PubMed Web of Science ®Google Scholar
• Younes A, Vose JM, Zelenetz AD, Results of a Phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL Receptor 1) in subjects with relapsed/refractory non-Hodgkin's lymphoma (NHL). Blood (ASH Annual Meeting Abstracts) 2005;106:489
   Google Scholar
• Kanzler S, Trarbach T, Heinemann V, Results of a Phase 2 trial of HGS-ETR1 (agonistic human monoclonal antibody to TRAIL Receptor 1) in subjects with relapsed or refractory colorectal cancer (CRC). Eur J Cancer Suppl 2005;3:630
   Google Scholar
• Leong S, Cohen RB, Gustafson DL, Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: Results of a phase 1 and pharmacokinetic study. J Clin Oncol 2009;27:4413-21
   PubMed Web of Science ®Google Scholar
• Mom CM, Verwej J, Oldenhuis CNAM, Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: A phase I study in patients with advanced solid malignancies. Clin Cancer Res 2009;15:5584-90
   PubMed Web of Science ®Google Scholar
• Zeng Y, Wu XX, Fiscella M, Monoclonal antibody to tumor necrosis factor-related apoptosis inducing ligand receptor 2 (TRAIL-R2) induces apoptosis in primary renal cell carcinoma cells in vitro and inhibits tumor growth in vivo. Int J Oncol 2006;28:421-30
   PubMed Web of Science ®Google Scholar
• Georgakis GV, Li Y, Humphreys R, Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: Induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005;130:501-10
   PubMed Web of Science ®Google Scholar
• Shimada O, Wu X, Jin X, Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells. Urology 2007;69:395-401
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhang X, Barrisford GW, Olumi A. Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model. Cancer Lett 2007;251:146-57
   PubMedGoogle Scholar
• Corey A, Humphreys R, Shepard L. Preclinical pharmacokinetics/ pharmacodynamics of HGS-ETR2, an agonistic fully human monoclonal antibody to TRAIL receptor 2. AAPS National Biotechnology Conference 2005;273; available online at http://www.aapsj.org/abstracts/NBC_2005/NBC05-000273.pdf [last accessed 17 September 2009]
   Google Scholar
• Nawrocki ST, Carew JS, Douglas L, Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels. Cancer Res 2007;67:6987-94
   PubMed Web of Science ®Google Scholar
• Wu XX, Jin XH, Zeng Y, Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression. Cancer Sci 2007;98:1969-76
   Google Scholar
• Vega MI, Huerta-Yepez S, Baritaki S, Rituximab sensitizes TRAIL-resistant B-NHL lines to apoptosis by both TRAIL and fully humanized antibodies targeting TRAIL-R1 (mapatumumab) and TRAIL-R2 (lexatumumab). Blood (ASH Annual Meeting Abstracts) 2007;110:2350
   Google Scholar
• Saulle E, Petronelli A, Pasquini L, Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis. Apoptosis 2007;12:635-55
   PubMed Web of Science ®Google Scholar
• Plummer R, Attard G, Pacey S, Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin Cancer Res 2007;13:6187-94
   PubMed Web of Science ®Google Scholar
• Wakelee H, Patnaik A, Sikic BI, Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors. Ann Oncol 2009; published online 24 July 2009, doi:10.1093/annonc/mdp292
   Google Scholar
• Sikic BI, Wakelee HA, von Mehren M, A phase Ib study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI. ASCO Meeting Abstracts 2007;25:14006
   Google Scholar
• Ashkenazi A, Adams C, Totpal K, Anti-tumor activity of Apomab: a fully human agonistic monoclonal antibody that targets the pro-apoptotic receptor DR5. AACR Meeting Abstracts 2007;48:LB-317
   Google Scholar
• Jin H, Yang R, Ross J, Cooperation of the agonistic DR5 antibody Apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Clin Cancer Res 2008;14:7733-40
   PubMed Web of Science ®Google Scholar
• Adams C, Totpal K, Lawrence D, Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 2008;15:751-61
   PubMed Web of Science ®Google Scholar
• Daniel D, Yang B, Totpal K, Activity of Apomab, a fully human agonistic DR5 monoclonal antibody, in models of non-Hodgkin's lymphoma. AACR Meeting Abstracts 2007;48:B32
   Google Scholar
• Zinonos I, Labrinidis A, Liapis V, Apomab, a fully human agonistic DR5 monoclonal antibody inhibits tumor growth and osteolysis in murine models of breast cancer development and progression. AACR Meeting Abstracts 2009;50;1239
   Google Scholar
• Camidge D, Herbst RS, Gordon M, A phase I safety and pharmacokinetic study of Apomab, a human DR5 agonist antibody, in patients with advanced cancer. ASCO Meeting Abstracts 2007;25:3582
   Google Scholar
• Kaplan-Lefko P, Gan Y, Huard J, AMG 655, a fully human agonistic antibody against TRAIL receptor-2, induces apoptosis via caspase activation in vitro and in vivo. AACR Meeting Abstracts 2007;48:4867
   Google Scholar
• Wall J, Colloton M, Huard J, AMG 655, a monoclonal antibody agonist directed against death receptor 5, induces apoptosis in human colon carcinoma cell lines and its therapeutic potential is enhanced in combination with chemotherapeutic agents. AACR Meeting Abstracts 2008;49:1326
   Google Scholar
• Kaplan-Lefko P, Bush T, Belmontes B, AMG 655, a fully human agonistic antibody against death receptor 5, enhances the anti-tumor activity of gemcitabine in MiaPaCa2/T2, a pancreatic cancer model. AACR Meeting Abstracts 2008;49:3999
   Google Scholar
• LoRusso P, Hong D, Heath E, First-in-human study of AMG 655, a pro-apoptotic TRAIL receptor-2 agonist, in adult patients with advanced solid tumors. ASCO Meeting Abstracts 2007;25:3534
   Google Scholar
• Saltz L, Infante J, Schwartzberg L, Safety and efficacy of AMG 655 plus modified FOLFOX6 (mFOLFOX6) and bevacizumab (B) for the first-line treatment of patients (pts) with metastatic colorectal cancer (mCRC). ASCO Meeting Abstracts 2009;27:4079
   Google Scholar
• Rougier P, Infante J, Van Laethem J, A phase Ib/II trial of AMG 655 and panitumumab (pmab) for the treatment (tx) of metastatic colorectal cancer (mCRC): safety results. ASCO Meeting Abstracts 2009;27:4130
   Google Scholar
• Kindler HL, Garbo L, Stephenson J, A phase Ib study to evaluate the safety and efficacy of AMG 655 in combination with gemcitabine (G) in patients (pts) with metastatic pancreatic cancer (PC). ASCO Meeting Abstracts 2009;27:4501
   Google Scholar
• Buchsbaum DJ, Zhou T, Grizzle WE, Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin Cancer Res 2003;9:3731-41
   PubMed Web of Science ®Google Scholar
• Yada A, Yazawa M, Ishida S, A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes. Ann Oncol 2008;19:1060-7
   PubMed Web of Science ®Google Scholar
• DeRosier LC, Vickers SM, Zinn KR, TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth. Mol Cancer Ther 2007;6:3198-207
   PubMed Web of Science ®Google Scholar
• DeRosier LC, Buchsbaum DJ, Oliver PG, Combination treatment with TRA-8 anti–death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer. Clin Cancer Res 2007;13:5535s-43s
   PubMed Web of Science ®Google Scholar
• Oliver PG, LoBuglio AF, Zinn KR, Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11. Clin Cancer Res 2008;14:2180-9
   PubMed Web of Science ®Google Scholar
• Amm H, Buchsbaum D. Differences in TRA-8 anti-DR5 antibody response with adriamycin by modulation of Akt, cell cycle and apoptotic pathways. AACR Meeting Abstracts 2008;49:LB-228
   Google Scholar
• Frederick PJ, Kendrick JE, Straughn JM, Effect of TRA-8 anti-DR5 monoclonal antibody in combination with chemotherapy in an ex vivo human ovarian cancer model. ASCO Meeting Abstracts 2008;26:14695
   Google Scholar
• Kim H, Morgan DE, Buchsbaum DJ, Early therapy evaluation of combined anti–death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res 2008;68:8369-76
   PubMed Web of Science ®Google Scholar
• Fiveash JB, Buchsbaum DJ, Gillespie GY. TRAIL death receptor therapy for malignant glioma. ASCO Meeting Abstracts 2005;23:3187
   Google Scholar
• Arafat WO, Buchsbaum DJ. TRAIL-mediated induction of apoptosis as a targeted therapy for prostate cancer. ASCO Meeting Abstracts 2005;23:3186
   Google Scholar
• Kim H, Chaudhuri TR, Buchsbaum DJ, High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m–labeled anti-DR5 antibody in breast tumor xenografts. Mol Cancer Ther 2007;6:866-75
   PubMed Web of Science ®Google Scholar
• Rajeshkumar N, Rasheed Z, Garcia-Garcia E, Tigatuzumab (CS-1008), a novel humanized DR5 agonist antibody, eradicates pancreas cancer stem cells and results in long term cures, in combination with gemcitabine, in direct pancreas cancer xenografts. AACR Meeting Abstracts 2009;50:1069
   Google Scholar
• Saleh MN, Percent I, Wood TE, A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphomas. ASCO Meeting Abstracts 2008;26:3537
   Google Scholar
• Li J, Tang B, Cheng J, Antitumor efficacy of LBY135, an anti-DR5 monoclonal antibody, alone or in combination with chemotherapy in human colon tumor cell lines and xenografts. AACR Meeting Abstracts 2007;48:4874
   Google Scholar
• Li J, Zhang Q, Johnson J, Tumor-cell specific cytotoxic activity of LBY135, a novel anti- DR5 agonistic antibody. AACR Meeting Abstracts 2007;48:4875
   Google Scholar
• Sharma S, de Vries EG, Infante JR, Phase I trial of LBY135, a monoclonal antibody agonist to DR5, alone and in combination with capecitabine in advanced solid tumors. ASCO Meeting Abstracts 2008;26:3538
   Google Scholar
• Humphreys RC, Shepard L, Poortman C, HGS-TR2J, an agonistic, TRAIL receptor 2 monoclonal antibody, actively and rapidly stimulates the TRAIL receptor pathway that leads to significant inhibition of tumor growth in human tumor cell lines in vitro and in vivo. AACR Meeting Abstracts 2005;46:1038
   Google Scholar
• Motoki K, Mori E, Matsumoto A, Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor–related apoptosis-inducing ligand receptor 2. Clin Cancer Res 2005;11:3126-35
   PubMed Web of Science ®Google Scholar
• Nagane M, Shimizu S, Mori E, Combined treatment with histone deacetylase inhibitors enhances cytotoxic activity of anti-DR5/TRAIL-R2 monoclonal antibodies in human glioma cells. AACR Meeting Abstracts 2008;49:1334
   Google Scholar
• Rowinsky EK. Targeted induction of apoptosis in cancer management: The emerging role of tumor necrosis factor–related apoptosis-inducing ligand receptor activating agents. J Clin Oncol 2005;36:9394-407
   Google Scholar
• Ashkenazi A, Herbst RS. To kill a tumor cell: The potential of proapoptotic receptor agonists. J Clin Invest 2008;118:1979-90
   PubMed Web of Science ®Google Scholar
• Hymowitz SG, O'Connell MP, Ultsch MH, A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 2000;39:633-40
   PubMed Web of Science ®Google Scholar
• Hymowitz SG, Christinger HW, Fuh G, Triggering cell death: The crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999;4:563-71
   PubMed Web of Science ®Google Scholar
• Kelley RF, Totpal K, Lindstrom SH, Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor–related apoptosis-inducing ligand reveal a greater contribution of Death Receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005;280:2205-12
   PubMed Web of Science ®Google Scholar
• Varfolomeev E, Maecker H, Sharp D, Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 2005;280:40599-608
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Pai RC, Fong S, Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999;104:155-62
   PubMed Web of Science ®Google Scholar
• Pollack IF, Erff M, Ashkenazi A. Direct stimulation of apoptotic signaling by soluble Apo2L/tumor necrosis factor–related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin Cancer Res 2001;7:1362-9
   PubMed Web of Science ®Google Scholar
• Jin H, Yang R, Fong S, Apo2 Ligand/tumor necrosis factor–related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival. Cancer Res 2004;64:4900-5
   PubMed Web of Science ®Google Scholar
• Daniel D, Yang B, Lawrence DA, Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts. Blood 2007;110:4037-46
   PubMed Web of Science ®Google Scholar
• Zhou Q, Fukushima P, DeGraff W, Radiation and the Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing Cyclin D1. Cancer Res 2000;60:2611-5
   PubMed Web of Science ®Google Scholar
• Ravi R, Jain AJ, Schulick RD, Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL. Cancer Res 2004;64:9105-14
   PubMed Web of Science ®Google Scholar
• Rosato RR, Almenara JA, Coe S, Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 2007;67:9490-500
   PubMed Web of Science ®Google Scholar
• Earel JK, VanOosten RL, Griffith TS. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor–related apoptosis-inducing ligand-resistant bladder tumor cells. Cancer Res 2006;66:499-507
   PubMed Web of Science ®Google Scholar
• Rosato RR, Almenara JA, Dai Y, Grant S. Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther 2003;2:1273-84
   Google Scholar
• Liu X, Yue P, Chen S, The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC Cells. Cancer Res 2007;67:4981-8
   PubMed Web of Science ®Google Scholar
• Lashinger LM, Zhu K, Williams SA, Bortezomib abolishes tumor necrosis factor–related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res 2005;65:4902-8
   PubMed Web of Science ®Google Scholar
• Herbst RS, Mendolson DS, Ebbinghaus S, A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. ASCO Meeting Abstracts 2006;24:3013
   Google Scholar
• Ling J, Herbst RS, Mendelson DS, Apo2L/TRAIL pharmacokinetics in a phase 1a trial in advanced cancer and lymphoma. ASCO Meeting Abstracts 2006;24:3047
   Google Scholar
• Xin Y, Tohnya TM, Herbst RS, Population pharmacokinetic (PPK) analysis of recombinant human Apo2L/TRAIL (rhApo2L/TRAIL) in a phase 1a study in advanced cancer and lymphoma. ASCO Meeting Abstracts 2008;26:2525
   Google Scholar
• Yee L, Fanale M, Dimick K, A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin's lymphoma. ASCO Meeting Abstracts 2007;25:8078
   Google Scholar
• Soria J, Smit EF, Khayat D, Phase Ib study of recombinant human (rh)Apo2L/TRAIL in combination with paclitaxel, carboplatin, and bevacizumab (PCB) in patients (pts) with advanced non-small cell lung cancer (NSCLC). ASCO Meeting Abstracts 2008;26:3539
   Google Scholar
• Yee L, Burris HA, Kozloff M, Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): Preliminary results. ASCO Meeting Abstracts 2009;27:4129
   Google Scholar
• van der Sloot AM, Tur V, Szegezdi E, Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci USA 2006;103:8634-9
   PubMed Web of Science ®Google Scholar
• Tur V, van der Sloot AM, Reis CR, DR4-selective tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. J Biol Chem 2008;283:20560-8
   PubMed Web of Science ®Google Scholar
• Szegezdi E, Mahalingam D, van der Sloot A, Decoy-insensitive TRAIL variants kill tumour cells more efficiently without damaging non-transformed cells. AACR Meeting Abstracts 2007;48:5170
   Google Scholar
• Griffith TS, Anderson RD, Davidson BL, Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol 2000;165:2886-94
   PubMed Web of Science ®Google Scholar
• VanOosten RL Griffith TS. Activation of tumor-specific CD8+ T cells after intratumoral Ad5-TRAIL/CpG Oligodeoxynucleotide combination therapy. Cancer Res 2007;67:11980-90
   PubMed Web of Science ®Google Scholar
• Griffith T, Konety B, Joudi F, Phase I study of Ad5-TRAIL in men with clinically organ confined prostate cancer. AACR Meeting Abstracts 2007;48:4870
   Google Scholar
• Gordon MS, Margolin K, Talpaz M, Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-50
   PubMed Web of Science ®Google Scholar
• Baselga J, Pfister D, Cooper MR, Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14
   PubMed Web of Science ®Google Scholar
• Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003;21:1404-11
   PubMed Web of Science ®Google Scholar
• Pazdur R. Endpoints for assessing drug activity in clinical trials. Oncologist 2008;13:19-21
   PubMed Web of Science ®Google Scholar
• Burzykowski T, Buyse M, Piccart-Gebhart MJ, Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008;26:1987-92
   PubMed Web of Science ®Google Scholar
• Llovet JM, Di Bisceglie AM, Bruix J, Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711
   PubMed Web of Science ®Google Scholar
• Schuetze SM, Baker LH, Benjamin RS, Canetta R. Selection of response criteria for clinical trials of sarcoma treatment. Oncologist 2008;13:32-40
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Schwartz L, Ricci S, Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24:4293-300
   PubMed Web of Science ®Google Scholar
• Llovet JM, Ricci S, Mazzaferro V, Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
   PubMed Web of Science ®Google Scholar
• Ricci MS, Kim SH, Ogi K, Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 2007;12:66-80
   PubMed Web of Science ®Google Scholar
• Kim SH, Ricci MS, El-Deiry WS. Mcl-1: A gateway to TRAIL sensitization. Cancer Res 2008;68:2062-4
   PubMed Web of Science ®Google Scholar
• Rosato RR, Almenara JA, Coe S, Grant S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res 2007;67:9490-500
   PubMed Web of Science ®Google Scholar
• Tse C, Shoemaker AR, Adickes J, ABT-263: A potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 2008;68:3421-8
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Mita A, Lewis LD, Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008;26:5198-203
   PubMed Web of Science ®Google Scholar
• Dean E, Jodrell D, Connolly K, Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer. J Clin Oncol 2009;27:1660-6
   PubMed Web of Science ®Google Scholar
• Thomas LR, Johnson RL, Reed JC, Thorburn A. The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation. J Biol Chem 2004;279:52479-86
   PubMed Web of Science ®Google Scholar
• Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signaling: Decisions between life and death. Int J Biochem Cell Biol 2007;39:1462-75
   PubMed Web of Science ®Google Scholar
• Büneker C, Mohr A, Zwacka RM. The TRAIL-receptor-1: TRAIL-receptor-3 and -4 ratio is a predictor for TRAIL sensitivity of cancer cells. Oncol Rep 2009;21:1289-95
   PubMed Web of Science ®Google Scholar